Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Clinical trial NCT05130970 · COMPLETED

Trial details

NCT number: NCT05130970
Sponsor: CSL Behring
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2022-02-03
Primary completion: 2024-01-02
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.